Basic Medical Theory Research

[1] Vu M,Yu J,Awolude O A,et al.Cervical cancer worldwide [J].Curr Probl Cancer,2018,42(5):457-465.
[2] 闫美辰,刘丽丽.宫颈癌流行病学及发病因素研究进展[J].锦州医科大学学报,2023,44(06):103-107+112.
[3] Chauhan S R,Bharadwaj M.Gearing up T-cell immunother apy in cervical cancer[J].Curr Probl Cancer,2018,42(2):175-188.
[4] Qian L,Zhang Y, Cui D, et al. Analysis of epidemiological trends in human papillomavirus infection among gynaecologic al outpatients in Hangzhou, China, 2011-2015[J]. BMC Infect Dis,2017,17(1):393.
[5] Doorbar J.Model systems of human papillomavirus-asso ciated disease[J].J Pathol,2016,238(2):166-79.
[6] 王伊洁,杨玮丽,李慰,等.宫颈高危型人乳头瘤病毒感染患者阴道微生态和外周血T淋巴细胞亚群分析[J].中国妇幼保健,2021,36(14):3342-3346.
[7] FengQ,Wei H,Morihara J,et al.Th2 type inflammation promot es the gradual progression of HPV-infected cervical cells to cervi cal carcinoma[J]. Gynecol Oncol,2012,127(2):412-9.
[8] 高慧芬.宫颈高危型HPV感染患者阴道微环境及外周血免疫因子表达[J].中国计划生育学杂志,2022,30(02):424-429.
[9] RamachandranD, Schürmann P, Mao Q, et al. Association of genomic variants at the human leukocyte antigen locus with cervical cancer risk, HPV status and gene expression levels[J].Int J Cancer,2020,147(9):2458-2468.
[10] 李梅.宫颈局部炎性因子和T细胞亚群改变对高危型HPV感染的影响[J].全科医学临床与教育,2019,17(06):516-519.
[11] 陈革,徐宏仙,许浪萍,等.HPV感染宫颈病变患者Th17细胞、IL-2、IL-10、E2F-1蛋白水平及其临床意义[J].中华医院感染学杂志,2020,30(15):2357-2361.
[12] 高霞,张平,宋玉娥.血清细胞因子在宫颈癌发生发展中作用的研究进展[J].医学综述,2022,28(08):1550-1554.
[13] Heusinkveld M, De Vos Van Steenwijk P J, Goedemans R, et al. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macro phages by CD4+ Th1 cells[J].J Immunol,2011,187(3):1157-65.
[14] Jorgovanovic D, Song M, Wang L, et al. Roles of IFN-γin tumor progression and regression: a review[J]. Biomark Res, 2020,8:49.
[15] 李莉莉,李飞,张璋.宫颈癌患者血清Th相关细胞因子水平变化与病理特征和预后的关系分析 [J].中国卫生工程学,2024,23(01):124-125+128.
[16] 石笑瑜,周蓓蓓,来艺青,等.T细胞免疫与宫颈癌关系的研究进展[J].东南大学学报(医学版),2021,40(06):869-874.
[17] 国畅廓,刘安文.IL-4/IL-4R与肿瘤关系的研究进展[J].生命的化学,2017,37(03):413-418.
[18] Wang B,Wang H,Li P,et al.Relationships of interleukin -10 with the regulatory T cell ratio and prognosis of cervical cancer patients[J].Clinics(Sao Paulo),2018,73:e679.
[19] García-Rocha R,Moreno-Lafont M,Mora-García M L, et al.Mesenchymal stromal cells derived from cervical cancer tum ors induce TGF-β1 expression and IL-10 expression and secr etion in the cervical cancer cells, resulting in protection from cytotoxic T cell activity[J].Cytokine,2015,76(2):382-390.
[20] 余晓凤.宫颈高危型HPV感染者外周血T细胞亚群及其免疫因子变化分析[J].中国实验诊断学,2023,27(06):669-673.
[21] 姜爱华.宫颈癌患者HPV感染状况及外周血Th1/Th2细胞因子变化研究[J].实用癌症杂志,2021,36(04):555-558.
[22] BaisA G, Beckmann I, Lindemans J, et al. A shift to a peripheral Th2-type cytokine pattern during the carcinogene sis of cervical cancer becomes manifest in CIN III lesions[J]. J Clin Pathol,2005,58(10):1096-100.
[23] 马金枝,李巧莉,朱夕雅,等.宫颈癌患者血清Th1/Th2相关细胞因子表达与病理特征及预后关系[J].中国计划生育学杂志,2023,31(01):214-217.
[24] LinW,Zhang H L,Niu Z Y,et al.The disease stage-associa ted imbalance of Th1/Th2 and Th17/Treg in uterine cervical cancer patients and their recovery with the reduction of tumor burden[J].BMC Womens Health,2020,20(1):126.
[25] Alves J J P, De Medeiros Fernandes T a A, De Araújo J M G, et al. Th17 response in patients with cervical cancer[J]. Oncol Lett,2018,16(5):6215-6227.
[26] Chen Z, Ding J, Pang N, et al. The Th17/Treg balance and the expression of related cytokines in Uygur cervical cancer patients[J].Diagn Pathol,2013,8:61.
[27] Walch-Rückheim B,Ströder R,Theobald L,et al. Cervical Cancer-Instructed Stromal Fibroblasts Enhance IL23 Express ion in Dendritic Cells to Support Expansion of Th17 Cells[J].Cancer Res,2019,79(7):1573-1586.
[28] Punt S, Fleuren G J, Kritikou E, et al. Angels and demons:Th17 cells represent a beneficial response, while neutrophil IL-17 is associated with poor prognosis in squam ous cervical cancer[J]. Oncoimmunology,2015,4(1):e984539.
[29] Xue J,Wang Y,Chen C,et al.Effects of Th17 cells and IL-17 in the progression of cervical carcinogenesis with high-risk human papillomavirus infection[J].Cancer Med,2018,7(2):297-306.
[30] Hou F,Li Z, Ma D, et al. Distribution of Th17 cells and Foxp3-expressing T cells in tumor-infiltrating lymphocytes in patients with uterine cervical cancer[J]. Clin Chim Acta, 2012,413(23-24):1848-54.
[31] Punt S,Van Vliet M E,Spaans V M,et al.FoxP3(+)and IL-17(+)cells are correlated with improved prognosis in cervical adenocar cinoma[J].Cancer Immunol Immunother,2015,64(6):745-53.
[32] Shang B,Liu Y,Jiang S J,et al.Prognostic value of tumor -infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis[J].Sci Rep,2015,5:15179.
[33] Hou F, Ma D, Cui B.Treg cells in different forms of uterine cancer[J].Clin Chim Acta,2013,415:337-40.
[34] 于丹军,樊静,胡月,等.妇科肿瘤患者外周血中调节性T细胞和血清中TGF-β、IL-10的变化及相关性研究[J].河北医科大学学报,2016,37(11):1307-1311+1316.
[35] 黄群欢,洪岭,陶春林.不同分期宫颈癌患者外周血Treg和相关细胞因子差异分析[J].检验医学,2017,32(09):769-772.
[36] Bonin C M, Padovani C T J, Da Costa I P, et al. Detection of regulatory T cell phenotypic markers and cytokines in patients with human papillomavirus infection[J]. J Med Virol, 2019, 91(2): 317-325.
[37] Zhang J, Zhan J, Guan Z, et al. The prognostic value of Th17/Treg cell in cervical cancer: a systematic review and meta-analysis[J].Front Oncol, 2024,14:1442103.
[38] Lin W, Niu Z, Zhang H, et al. Imbalance of Th1/Th2 and Th17/Treg during the development of uterine cervical cancer [J].Int J Clin Exp Pathol,2019,12(9):3604-3612.